Literature DB >> 22465153

New insights from structural biology into the druggability of G protein-coupled receptors.

Jonathan S Mason1, Andrea Bortolato, Miles Congreve, Fiona H Marshall.   

Abstract

The recent availability of X-ray structures for diverse ligand-bound Family A G protein-coupled receptors (GPCRs) in multiple conformations (inactive form with an antagonist/inverse agonist bound and active form with an agonist bound) now enables rational drug design efforts that have historically been applied to soluble enzyme targets. Here, we review properties of these GPCR binding sites, using a unique combination of calculated physicochemical properties and water energetics (GRID, WaterMap and SZMAP) to provide a new perspective and rational assessment of druggability for each GPCR target binding site. Examples are described from several well-studied enzyme systems to support this advanced structure-based approach to assessing druggability and to contrast their properties with those of GPCRs. Changes in receptor conformations between the GPCR inactive and active forms evident from the protein structures are discussed, yielding important pointers for rational drug design of antagonists and agonists and a better understanding of GPCR activation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22465153     DOI: 10.1016/j.tips.2012.02.005

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  57 in total

Review 1.  Ubiquitination of G protein-coupled receptors: functional implications and drug discovery.

Authors:  Michael R Dores; JoAnn Trejo
Journal:  Mol Pharmacol       Date:  2012-06-14       Impact factor: 4.436

Review 2.  Atypical regulation of G protein-coupled receptor intracellular trafficking by ubiquitination.

Authors:  Michael R Dores; JoAnn Trejo
Journal:  Curr Opin Cell Biol       Date:  2013-12-07       Impact factor: 8.382

Review 3.  Tuning up the right signal: chemical and genetic approaches to study GPCR functions.

Authors:  Patrick M Giguere; Wesley K Kroeze; Bryan L Roth
Journal:  Curr Opin Cell Biol       Date:  2013-12-08       Impact factor: 8.382

Review 4.  Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders.

Authors:  Yu Chen; Krzysztof Palczewski
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-03-23       Impact factor: 13.820

5.  Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.

Authors:  Zhong Zheng; Xi-Ping Huang; Thomas J Mangano; Rodger Zou; Xin Chen; Saheem A Zaidi; Bryan L Roth; Raymond C Stevens; Vsevolod Katritch
Journal:  J Med Chem       Date:  2017-04-03       Impact factor: 7.446

Review 6.  Approaches to target tractability assessment - a practical perspective.

Authors:  Kristin K Brown; Michael M Hann; Ami S Lakdawala; Rita Santos; Pamela J Thomas; Kieran Todd
Journal:  Medchemcomm       Date:  2018-02-14       Impact factor: 3.597

Review 7.  Minireview: ubiquitination-regulated G protein-coupled receptor signaling and trafficking.

Authors:  Verónica Alonso; Peter A Friedman
Journal:  Mol Endocrinol       Date:  2013-03-07

8.  The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35.

Authors:  Amanda E MacKenzie; Gianluigi Caltabiano; Toby C Kent; Laura Jenkins; Jennifer E McCallum; Brian D Hudson; Stuart A Nicklin; Lindsay Fawcett; Rachel Markwick; Steven J Charlton; Graeme Milligan
Journal:  Mol Pharmacol       Date:  2013-10-10       Impact factor: 4.436

Review 9.  Structure of Class B GPCRs: new horizons for drug discovery.

Authors:  Andrea Bortolato; Andrew S Doré; Kaspar Hollenstein; Benjamin G Tehan; Jonathan S Mason; Fiona H Marshall
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

10.  Surface coatings alter transcriptional responses to silver nanoparticles following oral exposure.

Authors:  Sameera Nallanthighal; Lukas Tierney; Nathaniel C Cady; Thomas M Murray; Sridar V Chittur; Ramune Reliene
Journal:  NanoImpact       Date:  2019-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.